Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1655923 · FYE Dec 31 · Prices AT CLOSE 2026-07-28 (USD) — end-of-day, never a live or intraday quote
Last $8.41Day −1.98%Mkt cap $183M1Y −13.6%Off 52W high −17.1%Vol (1Y) 70.7%
Daily closing price, split-adjusted to the current basis; 1.7y shown of 416 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest1.0% of sh out |
| Days to cover3.5d |
| 13F net flow (QoQ)+3.33% |
| Top-10 13F concentration96.8% |
| Next report (est.)2026-08-13 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$10.8M |
| Earnings (TTM)-$25.4M |
| ROE−40.7% |
| Net margin−202.2% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+29.4% |
| 1Y−13.6% |
| Since incept. (ann.)+25.6% |
Total return through 2026-07-28 · series begins 2024-11-12. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)70.7% |
| Ann. volatility (3Y)78.0% |
| Sharpe (1Y)0.14 |
| Sharpe (3Y)0.68 |
| Max drawdown (1Y)−55.0% |
| Max drawdown (3Y)−60.0% |
| Beta (3Y vs SPY)1.34 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Opaleye Management Inc. | 2.6M | $14M | 11.77% | +23.7% |
| Solas Capital Management, LLC | 1.9M | $11M | 8.84% | −2.2% |
| AWM Investment Company, Inc. | 1.7M | $9M | 7.68% | +0.0% |
| Cable Car Capital, LP | 1.4M | $8M | 6.35% | +30.4% |
| Ikarian Capital, LLC | 1.1M | $6M | 4.85% | +0.0% |
| SPHERA FUNDS MANAGEMENT LTD. | 567,616 | $3M | 2.61% | +0.0% |
| Alyeska Investment Group, L.P. | 365,000 | $2M | 1.68% | +0.0% |
| BOOTHBAY FUND MANAGEMENT, LLC | 256,393 | $1M | 1.18% | +0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-14 | −$0.32 | — | $3.5M | +20.7% |
| 2025-12-31 | 2026-03-26 | — | — | $2.8M | — |
| 2025-09-30 | 2025-11-13 | −$0.30 | — | $2.8M | — |
| 2025-06-30 | 2025-08-14 | −$0.65 | — | $1.7M | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-13 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
US 66% · CN 34%
geographic · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
